NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Editas Medicine, Inc. EDIT
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$40.5M
▲ 25.4% vs FY2024
EPS · FY25
$-1.80
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-198.1%
Net margin · FY25
-395.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 40.5M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 395 cents on every revenue dollar this year.
Per share
USD -1.80
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-198.1%
Return on equity, FY2025
ROE
Operating margin-394.9%
Net margin-395.0%
Return on assets-60.6%
Each USD of equity lost 198 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−14.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+27.1%
−14.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years+56.4%
Change, 10 years—
The share count grew 56% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 186.5M
total assets, end of FY2025
Total assetsUSD 186.5M
EquityUSD 27.3M
CashUSD 146.6M
Gross debtUSD 58.6M
Net debtUSD -88.0M
Current ratio3.54×
The company holds more cash than debt.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.1
0.0
0.0
0.1
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.2
−0.3
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.2
−0.2
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
Net income $B
−0.2
−0.2
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EPS, diluted $
−1.80
−2.88
−2.02
−3.21
−2.85
−1.98
−2.68
−2.33
−2.98
−3.02
−28.55
−12.46
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−198.1
−98.1
−43.2
−48.2
−40.6
−35.4
−53.6
−49.5
−70.2
−377.5
·
·
Shares out B
0.10
0.08
0.08
0.07
0.07
0.06
0.05
0.05
0.04
0.04
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed